Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

10 Questions For Bayer's UK CEO On Market Access Reforms In England

Executive Summary

Bayer AG's CEO for the UK and Ireland, Dr. Alexander Moscho, outlines his concerns about the reformed cancer drugs reimbursement system in England and Wales, which in October 2016 saw the first new drug introduced since an overhaul and relaunch earlier this year. Moscho also highlights his worries around proposals from NICE to introduce fees for appraisals of new medicines for use on the National Health Service, which he believes could taint the health technology appraisal committee's reputation and generate skepticism around its independence from industry.

You may also be interested in...



Formalizing 'Name And Shame': New Strategy To Rein In Price Increases

A bipartisan bill would require pharmaceutical manufacturers to provide notice and justification of any price increase over 10%. That formula resonates with Allergan’s recent price pledge, Hillary Clinton’s newest pricing oversight campaign proposal – and may be hard for industry to fend off in the context of must-pass user fee bills in 2017.

UK Cancer Drugs Fund Debuts To Muted Applause From Pharma, Charities

The re-launch of the controversial Cancer Drugs Fund in the UK has offered another point for debate about cancer drug pricing, budgetary pressures and the cost of innovation.

A Backstage View Of Roche’s Recent Collaborations

In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.

Topics

Related Companies

UsernamePublicRestriction

Register

PS119381

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel